Association results for hip OA meta-analysis of the discovery and the replication studies
| SNP | Chr | Gene | A1 | EAF (%) | Discovery stage | Replication stage | Combined | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | p Value | I2 (%) | OR (95% CI) | p Value | OR (95% CI) | p Value | I2 (%) | H&E RE p value | |||||
| Combined analysis of both genders: | |||||||||||||
| rs6094710 | 20q13 | NCOA3 | A | 4 | 1.40 (1.24 to 1.58) | 5.6×10−8 | 0 | 1.20 (1.08 to 1.34) | 7.3×10−4 | 1.28 (1.18 to 1.39) | 7.9×10−9 | 64 | 2.0×10−10 |
| rs1577792 | 6q14 | HMGN3 | A | 39 | 1.14 (1.09 to 1.20) | 7.3×10−8 | 0 | 1.03 (0.99 to 1.07) | 0.17 | 1.07 (1.04 to 1.11) | 7.8×10−5 | 50 | 9.6×10−6 |
| rs5009270 | 7q31 | IFRD1 | A | 30 | 1.15 (1.09 to 1.21) | 5.7×10−7 | 21 | 1.05 (1.00 to 1.11) | 0.061 | 1.10 (1.06 to 1.14) | 9.0×10−7 | 46 | 3.1×10−6 |
| rs10773046 | 12q24 | DNAH10 | G | 45 | 1.13 (1.08 to 1.19) | 9.7×10−7 | 10 | 1.01 (0.96 to 1.06) | 0.72 | 1.07 (1.03 to 1.11) | 2.0×10−4 | 64 | 1.9×10−6 |
| rs17610181 | 17q23 | NACA2 | A | 14 | 1.20 (1.11 to 1.29) | 1.9×10−6 | 32 | 1.05 (0.99 to 1.12 | 0.12 | 1.12 (1.06 to 1.18) | 1.3×10−5 | 42 | 7.5×10−6 |
| Female-specific analysis: | |||||||||||||
| rs10878630 | 12q15 | DYRK2 | A | 41 | 1.19 (1.11 to 1.26) | 1.2×10−7 | 25 | 0.98 (0.91 to 1.05) | 0.52 | 1.09 (1.04 to 1.14) | 3.9×10−4 | 65 | 1.1×10−5 |
| Male-specific analysis: | |||||||||||||
| rs12551314 | 9q22 | PHF2 | A | 12 | 1.30 (1.18 to 1.44) | 6.3×10−7 | 28 | 0.98 (0.86 to 1.11) | 0.72 | 1.16 (1.07 to 1.25) | 2.9×10−4 | 66 | 4.3×10−5 |
| rs3757837 | 7p13 | CAMK2B | C | 6 | 1.46 (1.26 to 1.69) | 8.3×10−7 | 46 | 1.15 (1.00 to 1.32) | 0.044 | 1.27 (1.15 to 1.41) | 2.2×10−6 | 78 | 7.7×10−10 |
The discovery sample set comprised 4349 hip OA cases and 46 903 controls, and the replication samples were 6928 cases and 20 570 controls in the analysis of both genders. The female-specific analysis comprised 2689 hip OA cases and 25 384 controls in the discovery set and 2398 cases and 8787 controls in the replication stage. For the male-specific analysis there were 2045 hip OA cases and 20 823 controls in the discovery set and 1386/7087 and 1451/4956 cases/controls in the replication stage for rs12551314 and rs3757837 respectively.
A1, coded/effect allele; Chr, chromosome; EAF, effect allele frequency; Gene, nearest gene; HE RE P, Han & Eskin Random Effects P; I2, measure of heterogeneity; OA, osteoarthritis.